


# Schedule of Accreditation

issued by

## United Kingdom Accreditation Service

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

 <b>Accredited to ISO 15189:2022</b>	<b>NHS Grampian</b>	
	<b>Issue No:</b> 009 <b>Issue date:</b> 05 June 2025	
	<b>Medical Genetics Department</b> <b>Polwarth Building</b> <b>Aberdeen Royal Infirmary</b> <b>Cornhill Road</b> <b>Aberdeen</b> <b>AB25 2ZD</b>	<b>Contact:</b> Christine Bell <b>Tel:</b> +44 (0) 1224 550681 <b>E-Mail:</b> christine.bell@nhs.scot <b>Website:</b> www.nhsgrampian.org/medicalgenetics
<b>Testing performed at the above address only</b>		

### DETAIL OF ACCREDITATION

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<b>HUMAN TISSUE AND FLUIDS</b>  Whole Blood Amniotic Fluid CVS Foetal blood Products of conception Tissue biopsy	<u>Cytogenetics</u>  Chromosome analysis for: Constitutional disorders Prenatal Diagnosis Reproductive Medicine Disorders Developmental Disorders Chromosome Breakage Disorders	Documented in-house methods for Chromosome culture by in-house procedures using Amniomax, HAMS F10, 199 Medias CYT PND 002, 005, 006, 007, 008, 021; CYT BLO 002 CYT INST 001-006  Followed by: Preparation of material for chromosome analysis by manual harvest using procedures CYT PND 004, 011, 012, 019, CYT BLO 004, 005, 006 CYT INST 005




8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p><b>HUMAN TISSUE AND FLUIDS (cont'd)</b></p> <p>Whole Blood Amniotic Fluid CVS Foetal blood Products of conception Tissue biopsy (cont'd)</p>	<p><u>Cytogenetics</u> (cont'd)</p> <p>Chromosome analysis for: Constitutional disorders Prenatal Diagnosis Reproductive Medicine Disorders Developmental Disorders Chromosome Breakage Disorders (cont'd)</p>	<p>Documented in-house methods for Chromosome culture by in-house procedures using Amniomax, HAMS F10, 199 Medias CYT PND 002, 005, 006, 007, 008, 021; CYT BLO 002 CYT INST 001-006</p> <p>The above followed by any combination of the following and Applied Spectral Imaging Image Analysis System SOP : CYT ANAL 005 and CYT INST 005</p> <p>a) G Banding - Microscopic detection using procedures CYT PND 018 CYT BLO 007</p> <p>b) Solid Staining and SCE staining with Microscopic detection using procedures CYT GEN 008 CYT INST007</p> <p>c) Fluorescence In situ Hybridisation (FISH) Documented in house methods using commercial kits from Abott (Vysis), Cytocell, Kreatech, and TCAG and in-house manual processing - Microscopic detection CYT FISH 018</p>
<p>Whole Blood Culture fibroblasts Chorion Skin Muscle Foetal material dissected from POC (products of conception)</p> <p>Amniotic Fluid CVS</p>	<p>Constitutional disorders</p>	<p>Documented in-house methods for DNA extraction using in-house procedures MOL EXTR 007, 009</p> <p>iGENATAL DNA extraction SOP: CYT ARRAY 007</p>



issued by

2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**Issue No: 009      Issue date: 05 June 2025**

**Testing performed at main address only**

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p>HUMAN TISSUE AND FLUIDS</p> <p>Solid Tumours</p> <p>Bone marrow</p> <p>Lymph node</p> <p>Whole blood</p> <p>Pleural Infusions</p> <p>Any malignant solid body tumour or fluid</p>	<p><u>Molecular Pathology</u></p> <p>Chromosome analysis for haemato-oncology and other oncology disorders</p>	<p>Chromosome culture by in-house procedures using commercial media (HAMS F10)</p> <p>CYT ACQ 007</p> <p>CYT ACQ 004, 005, 006, 008, 011, 013</p> <p>Followed by:</p> <p>Preparation of material for chromosome analysis by manual harvest using in-house methods</p> <p>CYT ACQ 009, 010</p> <p>and one or both of the following:</p> <p>a) G-Banding - Microscopic detection</p> <p>CYT ACQ 012</p> <p>b) Fluorescence In situ Hybridisation (FISH) by documented in house methods using Abbott (Vysis), Cytocell and Kreatech kits and in-house manual processing – Microscopic detection</p> <p>CYT FISH 018</p> <p>Treatment of FFPE sections by documented in house manual method</p> <p>CYT FISH 020, MOL EXTR 012</p> <p>Followed by:</p> <p>Fluorescence In situ Hybridisation (FISH) using documented in house methods and Abbott (Vysis), Cytocell and Kreatech kits with in-house manual processing – Microscopic detection</p> <p>CYT FISH 018</p>
<p>Paraffin embedded tissue sections</p>		



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p><b>HUMAN TISSUE AND FLUIDS (cont'd)</b></p> <p>Bone marrow Lymph node Whole blood Pleural Infusions Any malignant solid body tumour or fluid</p>	<p><u>Molecular Pathology</u> (cont'd)</p> <p>DNA and RNA-based molecular analysis for haemato-oncology disorders</p>	<p>Documented methods for DNA and RNA extraction using in-house procedures for manual or robotic extraction using QIASymphony and QIA EZ1 instruments, Biorobot and EZI XL and QIASymphony and QIA EZ1 kits</p> <p><u>Manual</u> MOL EXTR 002, 012, 008, CYT ACQM 003, 004</p> <p><u>Robotic</u> MOL EXTR 007, 009, 013</p>
<p>Plasma</p>	<p>cfDNA</p>	<p>Roche Cobas cfDNA preparation kit For downstream EGFR testing on Cobas SOPs: MOL EXTR 015, 016</p>
	<p>Mutation detection in the diagnosis and management of: AML / MDS CML / MPN ALL</p>	<p>PCR and RT PCR amplification of DNA / RNA (cDNA) using in house techniques. CYT ACQM 012, 002, 016, 018</p> <p>Followed by one of the following:</p> <ul style="list-style-type: none"> <li>a) Agarose gel electrophoresis MOL ELECT 002</li> <li>b) Fragment analysis by capillary electrophoresis on ABI3730 MOL EQUIP 008, 009</li> </ul> <p>Followed by Data analysis using GeneMarker CYT ACQM 005</p>
<p>Bone marrow Lymph node Whole blood Pleural Infusions Any malignant solid body tumour or fluid</p>	<p>CML / MPN ALL</p>	<p>(RT-q) PCR amplification of DNA / RNA (cDNA) using in house method and Qiagen kit with RotorGene 6000 CYT ACQM 006, 019</p>
<p>cDNA</p>	<p>MYD88 L265P Mutation</p>	<p>Realtime PCR and RotorgeneQ SOP:-CYT ACQM 020</p>



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	<u>Molecular Pathology</u> (cont'd)	
DNA	FLT3-TKD mutations	Fragment length polymorphism-mediated PCR assay (PCR followed by enzyme ECORV1 digest and resolution by fragment analysis ABI3730) CYT ACQM 016
	Clonality assessment of suspected lymphoproliferative disorders	Commercial kit (InVivoScribe) Fragment analysis on ABI3730 Data analysis using GeneMarker CYT ACQM 005
Paraffin embedded tissue sections	Mutation detection and screening: Lung cancer Colorectal cancer Melanoma Ovarian cancer Breast cancer	PCR amplification of DNA/RNA (cDNA) using in house methods and commercial kits MOL PCR 001 MOL PATH 003  Using a combination of techniques below:  a) Fragment length analysis (FLA) using ABI 3730 capillary electrophoresis MOL EQUIP 008, 009 MOL PATH 002  b) Sequence analysis on ABI3730 platform. Data analysis Mutation Surveyor MOL SEQ 001 MOL EQUIP 008, 009 MOL PATH 002
DNA from FFPE	Micro satellite instability (MSI)	In house methodology for evaluation of colo-rectal tumour samples only SOP:MOL PATH 001, 005



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p>HUMAN TISSUE AND FLUIDS (cont'd)</p> <p>Paraffin embedded tissue sections</p> <p>cfDNA</p> <p>Whole Blood Foetal Blood Mouth washes Amniotic Fluid CVS Products of Conception Fresh tissue (tumour, muscle, liver, lymph nodes etc) Bone Marrow Wax embedded tissue Slide sections DNA</p>	<p><u>Molecular Pathology</u> (cont'd)</p> <p><u>Molecular Genetics</u></p> <p>DNA and RNA (cDNA)-based detection of abnormal sequences for common and rare genetic disease conditions</p>	<p>c) Mutation detection on the Cobas platform using kits as below Roche Cobas EGFR Roche Cobas KRAS Roche Cobas BRAF V600 MOL PATH 003</p> <p>Roche Cobas EGFR SOPs: MOL PATH, 001, 003 , 006</p> <p>Documented in-house methods for DNA and RNA extraction using in-house procedures using commercial kits and manual or robotic extraction using QIASymphony and QIA EZ1 instruments and kits <u>Manual</u> MOL EXTR 002, 012, 008 <u>Robotic</u> MOL EXTR 007, 009, 013</p> <p>PCR amplification of DNA/RNA (cDNA) using in house methods and commercial kits MOL PCR 001 MOL QFPCR 005</p> <p>Followed by (as appropriate): Capillary electrophoresis by in house methods using ABI 3730 genetic analyser MOL SEQ 001 MOL EQUIP 008, 009</p>



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p><b>HUMAN TISSUE AND FLUIDS (cont'd)</b></p> <p>Whole Blood, Foetal Blood Mouth washes, Amniotic Fluid CVS, Products of Conception Fresh tissue (tumour, muscle, liver, lymph nodes etc), Bone Marrow Wax embedded tissue, Slide sections, DNA</p> <p>DNA extracted from whole blood (EDTA preserved), amniotic fluid, chorionic villus sampling, saliva.</p> <p>Whole Blood, Foetal Blood Mouth washes, Amniotic Fluid CVS, Products of Conception Fresh tissue (tumour, muscle, liver, lymph nodes etc), Bone Marrow Wax embedded tissue Slide sections, DNA</p>	<p><u>Molecular Genetics</u> (cont'd)</p> <p>DNA and RNA (cDNA)-based detection of abnormal sequences for common and rare genetic disease conditions (cont'd)</p> <ul style="list-style-type: none"> <li>Rapid Prenatal diagnosis of Trisomies</li> </ul> <p>DNA profiling</p> <ul style="list-style-type: none"> <li>Detection of maternal cell contamination (MCC)</li> </ul> <p>Deletion and duplication detection</p> <ul style="list-style-type: none"> <li>Breast/ovarian cancer</li> <li>HMSN/HLPP</li> <li>Hyperlipidaemia</li> <li>Li-Fraumeni</li> <li>PTEN Hamartoma Tumour syndrome (PHTS)</li> </ul> <p>Detection of specific wild type and mutant alleles in the CFTR gene</p> <p>Unstable repeat measurement and Specific mutation detection:</p> <ul style="list-style-type: none"> <li>Myotonic Dystrophy types 1 and 2,</li> <li>Fragile X</li> <li>Torsion dystonia</li> <li>ARX</li> <li>GRA</li> </ul>	<p>Using Elucigene kits as below QST*R plus QST*R 13 QST*R 18 QST*R 21 MOL QFPCR 005, 007, 008</p> <p>Promega Powerplex using MOL QFPCR 005, 007, 008 and MOL PROF 001</p> <p>Multiplex Ligation Probe Amplification (MLPA) to detect characteristic mutations and larger intragenic deletions and duplications using MRC-Holland kit MOL MLPA 001, 002</p> <p>Fragment length analysis on ABI3730 platform with data analysis on GeneMarker MOL CF 004</p> <p>Fragment length analysis (FLA) ABI 3730 capillary electrophoresis MOL EQUIP 008, 009</p> <p>MOL DM 003, MOL DM 004</p> <p>MOL FRAX 001 MOL DYT 001 MOL ARX 001 MOL GRA 001</p>



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**

**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p><b>HUMAN TISSUE AND FLUIDS (cont'd)</b></p> <p>Whole Blood, Foetal Blood Mouth washes, Amniotic Fluid CVS, Products of Conception Fresh tissue (tumour, muscle, liver, lymph nodes etc), Bone Marrow Wax embedded tissue Slide sections, DNA (cont'd)</p>	<p><u>Molecular Genetics</u> (cont'd)</p> <p>Mutation detection by DNA sequencing:</p> <ul style="list-style-type: none"> <li>Breast/ovarian cancer</li> <li>Cardiac disorders</li> <li>PTEN Hamartoma Tumour syndrome (PHTS)</li> <li>Haemochromatosis</li> <li>HMSN (all types)</li> <li>Hyperlipidaemia</li> <li>Li Fraumeni</li> <li>RR-MADD</li> <li>Sickle cell mutation EB7</li> <li>Thrombophilia</li> </ul> <p>Rare disorders:</p> <ul style="list-style-type: none"> <li>Non-syndromic X-linked mental retardation</li> <li>Trimethylaminuria</li> <li>Familial Mediterranean fever</li> <li>Methylmalonic aciduria</li> </ul>	<p>Sequence analysis on ABI3730 platform. Data analysis Mutation Surveyor MOL EQUIP 009 MOL SEQ 008 With specific reference to the procedures below as appropriate</p> <p>MOL BRCA 003, 006, 007 MOL LQT 003, 007 MOL ARVC 009, 005 MOL CPVT 004, 005 MOL PTEN 003, 004</p> <p>Sequence analysis on ABI3730 platform. Data analysis Mutation Surveyor MOL EQUIP 009 MOL SEQ 008 With specific reference to the procedures below as appropriate</p> <p>MOL HFE 001 MOL HMSN 017, 018, 012 MOL FH 002, 005 MOL APOE 001 MOL TRIG 001 MOL LI-FR 001, 004 MOL MADD 002 MOL SICK 001 MOL THROM 001</p> <p>MOL RARE 001 MOL TMA 001 MOL FMF 001 MOL CBC 001</p>





8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009    Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
<p><b>HUMAN TISSUE AND FLUIDS (cont'd)</b></p> <p>Whole Blood, Foetal Blood Mouth washes, Amniotic Fluid CVS, Products of Conception Fresh tissue (tumour, muscle, liver, lymph nodes etc), Bone Marrow Wax embedded tissue Slide sections, DNA (cont'd)</p>	<p><u>Molecular Genetics</u> (cont'd)</p> <p>Mutation detection by DNA sequencing: (cont'd)</p>	<p>Sequence analysis on ABI3730 platform. Data analysis Mutation Surveyor MOL EQUIP 009 MOL SEQ 008 With specific reference to the procedures below as appropriate</p>
DNA	<p>Cardiac Arrhythmias Sub panels</p> <ul style="list-style-type: none"> <li>• Arrhythmogenic Right Ventricular Cardiomyopathy</li> <li>• Atrial Fibrillation</li> <li>• Brugada Syndrome</li> <li>• Catecholaminergic polymorphic ventricular tachycardia (CPVT)</li> <li>• Dilated Cardiomyopathy</li> <li>• Heart Block</li> <li>• Long QT</li> <li>• Long QT – Andersen syndrome</li> <li>• Sudden Cardiac Death</li> </ul>	<p>Custom Cardio Solution NGS panel for Cardiac Arrhythmias, sequencing by MiSeq and analysis of sub-panels through commercial Sophia DDM pipeline. MOL NGS 006, 016</p> <p>SOP: MOL CARD 001</p>
DNA	Hereditary Cancer Solution for breast and ovarian cancer,	<p>Breast and ovarian cancer, sequencing by MiSeq and analysis through commercial Sophia DDM pipeline (Germline).</p> <p>SOP: MOL BROV 001 MOL NGS 006, 016</p>
DNA	SPIDeR SEQ panel	<p>(Scottish Primary Immune Deficiency and Rheumatology NGS SEQ panel) - custom design kit based on Twist Custom Design library preparation, sequencing by MiSeq and analysis by commercial Sophia DDM pipeline (CVID). SOP: MOL NGS 019 ,MOL NGS 008</p>



8141  
Accredited to  
ISO 15189:2022

**Schedule of Accreditation**  
issued by  
**United Kingdom Accreditation Service**  
2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

**NHS Grampian**  
**Issue No: 009 Issue date: 05 June 2025**

Testing performed at main address only

Materials/Products tested	Type of test/Properties measured/Range of measurement	Standard specifications/ Equipment/Techniques used
HUMAN TISSUE AND FLUIDS (cont'd)	<u>Molecular Genetics</u> (cont'd)	
DNA	Myeloid Panel Detection of mutations in MDS and AML	Thermo Fisher Myeloid Oncomine NGS DNA panel Set up on Ion Chef ) and sequencing by and Ion Torrent S5. Analysis through commercial Ion Reporter Analysis Pipeline  SOP: MOL NGS 013, 003
RNA /cDNA	Myeloid Panel Detection of fusion gene / translocation detection in haematological malignancies	Thermo Fisher Oncomine Myeloid RNA Assay Set up on Ion Chef and sequencing by Ion Torrent S5. Analysis through commercial Ion Reporter Analysis Pipeline.  SOP: MOL NGS 018, 015
DNA	Fragment size data	Agilent Tapestation 4200 for QC and DNA NGS Libraries  SOP: MOL NGS 017
END		